AM630 is primarily used in scientific research to study the endocannabinoid system. It acts as a selective antagonist for the CB2 receptor, making it a valuable tool for investigating immune system responses and inflammatory processes. Researchers use AM630 to block CB2 receptor activity in cellular and animal models, helping to clarify the role of these receptors in pain, inflammation, and neurodegenerative conditions. It is also employed in studies exploring the effects of cannabinoids on cancer cells, immune function, and neurological disorders. Due to its specificity, AM630 allows for targeted modulation of CB2-mediated pathways without directly affecting CB1 receptors, which are associated with psychoactive effects.